Physician profile
Thomas T Chen
NPI 1992875538
$2,256.43
in general payments reported to CMS, 2019-2025
25 companies · $471 in 2025
The $471 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $137 · 2020: $234 · 2021: $472 · 2022: $258 · 2023: $321 · 2024: $364 · 2025: $471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,155.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $335.93 | 2019-2025 | |
| Glaxosmithkline, LLC. | $226.87 | 2019-2025 | Shingrix, Arexvy |
| Lilly USA, LLC | $190.12 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.47 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $175.96 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $153.79 | 2019-2023 | Farxiga |
| Amgen INC. | $117.19 | 2023-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $115.44 | 2020-2022 | |
| Amarin Pharma, INC. | $111.89 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.71 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $90.79 | 2022 | |
| Merck Sharp & Dohme LLC | $78.82 | 2020-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Esperion Therapeutics, INC. | $78.45 | 2021-2025 | Nexletol |
| Biohaven Pharmaceuticals, INC. | $69.31 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $32.75 | 2025 | Zoryve |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $32.06 | 2022 | |
| Azurity Pharmaceuticals, INC. | $26.19 | 2025 | Edarbi |
| Agios Pharmaceuticals, INC. | $22.20 | 2025 | Pyrukynd |
| Medtronic, INC. | $18.16 | 2021 | |
| Seqirus USA INC | $17.75 | 2025 | Flucelvax |
| Ethicon US, LLC | $16.56 | 2019 | |
| Eisai INC. | $16.47 | 2021 | |
| Bardy Diagnostics, INC. | $13.78 | 2021 | |
| Boston Scientific Corporation | $13.01 | 2020 | |
| Janssen Pharmaceuticals, INC | $12.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.